Introduction
============

Estrogens play an important role in the etiology of CRC ([@B8]). Pre-menopausal women are protected against CRC compared to age-matched men ([@B7]), and data from the Women's Health Initiative suggests post-menopausal women on HRT, a combination of estrone sulfate (E~1~S) and progestins, have a 40% reduced incidence of developing CRC compared to women not on HRT ([@B4]).

Despite this epidemiological evidence suggesting HRT as protective against CRC, evidence also exists showing estrogens influence CRC proliferation. For example, the CRC cell line Lovo increases proliferation, via a FASN-mediated mechanism, when exposed to estradiol (E~2~) ([@B31]). Indeed, E~2~ increases the proliferation of the CRC cell line Caco2 ([@B6]) and T84 ([@B12]), and inhibits apoptosis in DLD-1 cells ([@B17]). CRC patients on HRT present at a later and more advanced stage of disease ([@B4]), suggesting estrogens as mitogenic in CRC. Thus, the ability of CRC to take up and consequently metabolize E~1~S will define local concentrations of active estrogens and subsequent action.

Steroid sulfatase is the key enzyme involved in hydrolyzing E~1~S to E~1~ (**Figure [1](#F1){ref-type="fig"}**) ([@B20]), and its activity is known to directly increase the proliferation of estrogen-dependent breast cancer ([@B10]) and endometrial cancer ([@B11]). Inhibition of STS has shown significant promise against ERα positive breast cancer ([@B35]; [@B9]). Intriguingly, STS expression, elevated E~1~ and E~2~ intratumoural concentrations, are associated with a poor prognosis in CRC patients ([@B32]). This suggests that colonic estrogen metabolism may play an important role in CRC patient outcomes.

![**Steroid sulfatase activity in CRC cell lines.** E~1~S is transported across the cell membrane by OATPs and once intracellular E~1~S can be hydrolyzed by STS to form E~1~.](fphar-08-00103-g001){#F1}

However, very little is known about whether E~1~S is transported into CRC. Sulfated steroids require transport into cells via solute carrier organic anion transporting polypeptides (SLCO/OATP); membrane bound proteins that transport a plethora of organic anions ([@B30]). Six different SLCO/OATP (OATP1A2, OATP1B1, OATP1B3, OATP2B1, OATP3A1, OATP4A1) are known to effectively transport E~1~S ([@B20]), although their expression and action in CRC is poorly defined. Other OATPs are known to transport E~1~S (OATP4C1 and OATP1C1), however OATP4C1 is primarily expressed in the kidney ([@B18]), and microarray analysis shows it may have some expression in the liver but not the human colon ([@B1]). OATP1C1 is localized to human brain and testis ([@B23]), and is not evident in human colorectal tissue, as measure by microarray ([@B1]).

Here, we investigate STS activity and E~1~S transport kinetics in four CRC cell lines. We demonstrate that OATP4A1 is most likely the principle E~1~S transporter in CRC and that all cell lines have the ability to hydrolyze E~1~S. We also show that STS activity in CRC may be regulated by local E~2~ availability via a novel GPER mechanism.

Materials and Methods {#s1}
=====================

Compounds
---------

STX64 (Irosustat, 667COUMATE) was kindly supplied by Prof. Barry Potter (University of Oxford, UK). G1 and G15 were purchased from Torcis Bioscience (Abingdon, UK). E~2~, tamoxifen, fulvestrant, and BSP were purchased from Sigma-Aldrich (Dorset, UK).

Cell Culture
------------

The CRC cell lines Colo205, HCT116, and HT29 were purchased from the American Type Culture Collection, USA; Caco2 and JEG3 cells were purchased from The European Collection of Cell Cultures (ECACC). Prior to experiments, all cell lines were authenticated by short tandem repeat profiling and were used between passages 10 and 35. Furthermore, all experiments were performed during the exponential growth phase of the cell line. HCT116 and HT29 were routinely cultured in McCoy's 5a modified medium (Gibco, Life Technologies, USA) with 10% v/v heat inactivated FBS (Sigma-Aldrich, UK). Colo205 cells were culture in RPMI with 10% FBS; Caco2 cells were cultured in MEM with 10% FBS. JEG3 cells were cultured in DM-F12 (Gibco, USA) with 10% FBS. All culture mediums were supplemented with 2 mM [L]{.smallcaps}-glutamine (Sigma-Aldrich, UK) and 1% PenStrep (Gibco, USA). JEG3 cells were used as control as they exhibit high STS activity.

For experimental conditions, cells were initially starved of estrogens for 72 h by placing them in their appropriate phenol-red free medium plus 10% charcoal stripped FBS (sFBS) (Sigma-Aldrich, UK). After starvation, HCT116 and HT29 cells were treated with E~2~ (100 nM), G1 (100 nM), G15 (1 μM), Tamoxifen (10 nM) or fulvestrant (1 μM) in stripped medium for 24 h prior to measuring STS activity.

STS Activity Assay
------------------

*In vitro* STS activities of cell lines were measured as previously described ([@B26]). Briefly, in intact cell assays, cells were incubated with appropriate medium containing \[6,7-^3^H\] E~1~S (4 × 10^5^ dpm, Perkin-ElmerLS, Boston, MA, USA) adjusted to a final concentration of 20 μM with unlabeled E~1~S (Sigma-Aldrich, UK). \[4-^14^C\] E~1~ (1 × 10^4^ dpm, Perkin-Elmer) was also included in the reaction mixture to monitor procedural losses. Samples were incubated for 18 h at 37°C after which the product, E~1~, was separated from E~1~S by partition with toluene. A toluene aliquot was removed and ^3^H and ^14^C radioactivity measured by liquid scintillation spectrometry. The mass of E~1~S hydrolyzed was calculated from the ^3^H counts detected corrected for procedural losses. A protein measurement was obtained for the cells by lysing the cells with RIPA buffer (Sigma-Aldrich, UK) followed by a BCA assay (Thermo Fisher Scientific, UK).

To determine STS activity in cell lysates, cells were first lysed with RIPA buffer and protein content determined using a BCA assay. Subsequently, 100 μg of cell protein was incubated for 4 h with PBS containing \[6,7-^3^H\] E~1~S (4 × 10^5^ dpm) adjusted to a final concentration of 20 μM with unlabeled E~1~S. \[4-^14^C\] E~1~ (1 × 10^4^ dpm) was again used to monitor procedural losses. E~1~ was separated from E~1~S by partition with toluene and ^3^H and ^14^C radioactivity measured by liquid scintillation spectrometry. Results for both intact and cell lysates were determined as pmol E~1~ formed/h/mg protein.

qRT-PCR Analysis
----------------

From cells mRNA was purified from T75 flasks or six well plates at approximately 80% confluency using RNeasy kits (QIAGEN, Crawley, UK) and stored at -80°C. Aliquots containing 5 μg of mRNA were reverse transcribed in a final volume of 20 μl to form cDNA using Tetro cDNA Synthesis Kit (Bioline Reagents, Ltd, UK). RT-PCR reactions were performed in a 'Rotor Gene 2000 Real-Time Cycler' (Corbett Life Science, Cambridge, UK) with 1 μl cDNA in a final volume of 12 μl, using Taqman universal PCR master mix and Taqman expression assays containing primers and probes for OATP1A2, OATP1B1, OATP1B3, OATP2B1, OATP3A1, OATP4A1, and for the endogenous control gene, RPLP0 (Applied Biosystems, UK). In CRC, RPLPO is considered the most reliable single standard gene to examine ([@B33]). The conditions were as follows: 95°C for 10 min; followed by 40 cycles of 95°C for 15 s, and 60°C for 60 s. Relative mRNA expression was calculated using the comparative quantisation algorithm in the Rotor Gene 6 software (Corbett Life Science).

E~1~S Uptake Studies
--------------------

Cells were seeded at 200,000 cells per well in 6-well plates and allowed to acclimatize for 24 h. Appropriate phenol red free medium containing 10% sFBS plus \[6,7-^3^H\] E~1~S (4 × 10^5^ dpm) was placed on the cells and was subsequently removed after 2, 5, 10, 15, 20, 30 min. For OATP inhibition studies, the competitive OATP inhibitor BSP (at 1 μM) was added to the medium and therefore was present throughout the 30 min uptake time. The cells were then washed twice in PBS, lysed using RIPA buffer, and the intracellular ^3^H radioactivity measured by liquid scintillation spectrometry. Cell protein content was also determined with a BCA assay. Results are expressed as E~1~S uptake pmol/mg protein.

Immunoblotting
--------------

Protein concentration was determined from cell lysates using the BCA assay, and 15 μg samples were separated by electrophoresis under reducing conditions on 4--12% Bis-Tris 10% SDS-PAGE gels (Invitrogen, Paisley, UK) before being transferred to PVDF membranes. Membranes were immunoblotted with either ERα (1:1000), ERβ (1:1000), GPER (1:800) (all from Santa Cruz, UK), or β-actin (1:50,000) (Sigma-Aldrich, UK) monoclonal antibodies in incubation buffer containing 0.1% milk (Marvel; Premier Brands UK Ltd, Lincolnshire, UK) in TBST. For full details of antibodies and conditions used see **Table [1](#T1){ref-type="table"}**. Bound antibody was detected with horseradish peroxidase-conjugated anti-mouse or anti-rabbit secondary antibodies and chemiluminescence detection.

###### 

Information regarding antibodies and conditions used for immunoblotting.

  Antibody   Manufacturer, Cat. \#, Lot \#   Peptide/protein target                                     Species raised, monoclonal/polyclonal   Dilution used     Positive control
  ---------- ------------------------------- ---------------------------------------------------------- --------------------------------------- ----------------- ------------------
  ERα        Santa Cruz, sc-130072, C2910    aa 301--595                                                Mouse, monoclonal                       1:1000, 1% milk   MCF-7
  ERβ        Abcam, ab288, GR79420-5         aa 1--153                                                  Mouse, monoclonal                       1:1000, 1% milk   MCF-7
  GPER       Santa Cruz, sc-48525-R, F2414   N-terminus                                                 Rabbit, Polyclonal                      1:800, 5% milk    MCF-7
  β-actin    Sigma, A228                     slightly modified β-cytoplasmic actin N-terminal peptide   Mouse, Monoclonal                       1:50,000          

siRNA Transfection
------------------

Twenty four hours after seeding HCT116 cultures were transfected with OATP-specific and control siRNA (Thermo Fisher Scientific, UK) by lipofectamine-2000 (Invitrogen) using standard protocols. 72 h post-transfection, E~1~S uptake studies were performed over 30 min and total E~1~S uptake calculated.

Results
=======

STS Activity in Intact and Lysed CRC Cell Lines
-----------------------------------------------

The panel of four CRC cell lines, plus the positive control JEG3, were investigated and demonstrate a wide range of STS activity (**Figures [2A,B](#F2){ref-type="fig"}**). In intact (not lysed) cells, Caco2 exhibited the highest STS activity (65.47 ± 28.51 pmol/mg/h), with HCT116 cells having the lowest activity (1.65 ± 0.14 pmol/mg/h). STS activity could be almost completely inhibited in intact cells using 1 μM of the specific STS inhibitor STX64 (**Figure [2A](#F2){ref-type="fig"}**).

![**(A)** Steroid sulfatase activity (E~1~S conversion in pmol/mg/h) and inhibition by STX64 (1 μM) in intact CRC cell lines. **(B)** STS activity and inhibition by STX64 (1 μM) in CRC cell lysate. JEG3 cells were used as a positive control in all experiments. Data represents mean ± SD. *n* = 3 independent experiments.](fphar-08-00103-g002){#F2}

When lysed, the intracellular STS activity was much greater in all cell lines examined compared to their intact state (**Figure [2B](#F2){ref-type="fig"}**). STS activity was again greatest in the Caco2 cell lines (452.90 ± 56.34 pmol/mg/h) with HCT116 cell showing the lowest STS activity (11.87 ± 6.41 pmol/mg/h). These results demonstrate that E~1~S uptake kinetics most likely dictate the ability of CRC to hydrolyze E~1~. Therefore, as E~1~S is transported through the cell membrane by OATPs the expression of these transporters was next determined.

OATP Expression and E~1~S Uptake in CRC Cell Lines
--------------------------------------------------

The mRNA expression of OATPs known to transport E~1~S across the plasma membrane was determined in the panel of CRC cell lines (**Figure [3](#F3){ref-type="fig"}**). Of the six OATPs examined only OATP4A1 was present in all four cell lines. OATP2B1 expression was also notably high in Caco2 cells. The HT29 cells expressed five of the six OATPs determined (OATP1B3 was not present in HT29 cells), with the Caco2 cells expressing four (OATP1A1, OATP1B3, OATP2B1, OATP4A1) out of six. Our results are roughly consistent with the expression patterns obtained from the CellMiner database^[1](#fn01){ref-type="fn"}^, as shown by average transcript log^2^ intensities (see **Table [2](#T2){ref-type="table"}**).

![**Organic anion transporter polypeptide mRNA expression in Colo205, Caco2, HCT116, and HT-29 cells.** OATP4A1 expression was the highest in all cell lines. Data represents mean ± SD. *n* = 3 independent experiments.](fphar-08-00103-g003){#F3}

###### 

Average transcript log^2^ intensities determined from the National Cancer Institute (NCI) CellMiner database (<https://discover.nci.nih.gov/cellminer/>).

            1A2    1B1    1B3    2B1    3A1    4A1
  --------- ------ ------ ------ ------ ------ ------
  Colo205   3.24   3.22   5.50   7.29   4.76   8.38
  HCT116    2.96   3.23   5.75   5.34   4.61   8.19
  HT29      2.84   2.89   4.92   5.39   6.54   8.04

Average log

2

determined from mRNA various probes/probe sets.

When the ability of CRC cells to transport E~1~S into the cells was determined, Colo205 demonstrated the quickest uptake rate, with HCT116 cells having the slowest uptake (**Figure [4A](#F4){ref-type="fig"}**). Inhibition of OATP transport with the non-specific OATP inhibitor BSP significantly reduced E~1~S uptake in all four cell lines (**Figures [4B--E](#F4){ref-type="fig"}**). Caco2 cells had the most rapid with HCT116 cells exhibited the slowest E~1~S transport. E~1~S uptake after 30 min demonstrated that Colo205 (89.41 ± 16.80 pmol/mg) and Caco2 (61.78 ± 10.80 pmol/mg) cells exhibited the most intracellular E~1~S transport, with HCT116 (16.73 ± 6.80 pmol/mg) and HT29 (34.59 ± 5.63 pmol/mg) cells showing lower E~1~S transport (**Figure [4F](#F4){ref-type="fig"}**). BSP significantly (*p* \< 0.001) inhibited E~1~S transport in all four cell lines.

![**Estrone sulfate transport in Colo205, Caco2, HCT116 and HT-29 cells. (A)** Comparison of the different uptake kinetics of E~1~S over 30 min in four CRC cell lines. **(B)** Inhibition of Colo205 E~1~S transport by BSP (1 mM). **(C)** Inhibition of Caco2 E~1~S transport by BSP. **(D)** Inhibition of HCT116 E~1~S transport by BSP. **(E)** Inhibition of HT-29 E~1~S transport by BSP. **(F)** Total E~1~S uptake over 30 min by four CRC cell lines and the total inhibition caused by BSP. Data represents mean ± SD. *n* = 3 independent experiments. ^∗∗∗^*p* \< 0.001 compared to control.](fphar-08-00103-g004){#F4}

To examine if OATP inhibition by BSP reduces E~1~S intracellular substrate availability to STS, we examined the effect of BSP on STS activity in intact cells and cell lysates. We selected Caco2 and HCT116 cells as representative of CRC cells with high and low STS activity, respectively. In intact cells, treatment with BPS (1 μM) non-significantly reduced STS activity in Caco2 cells but had no effect on HCT116 STS activity (**Figure [5A](#F5){ref-type="fig"}**). When BPS (1 μM) was tested in cell lysates it had no effect on STS activity in both Caco2 and HCT116 cells, suggesting it does not directly inhibit the STS enzyme (**Figure [5B](#F5){ref-type="fig"}**). These results imply that OATP transport into cells plays a rate-limiting step on E~1~S STS hydrolysis. The discrepancy between Caco2 and HCT116 cells in response to BSP most likely represents the difference between the STS activity in the cell lines. When STS activity is high (Caco2), limiting E~1~S OATP transport limits intracellular E~1~S availability thus reducing E~1~ hydrolysis. When STS activity is low (HCT116), limiting E~1~S OATP transport does not directly translate to decreased hydrolysis as there is less STS activity, and thus limiting substrate availability via OATP inhibition and where enzyme activity is already low does not translate to reduced E~1~S hydrolysis.

![**Bromsulfthalein has limited effect on STS activity Caco2 and HCT116 cells. (A)** In intact cells, STS activity is non-significantly reduced by BSP (1 μM) in Caco2 cells and has no effect on HCT116 cells. **(B)** In cell lysates, BSP (1 μM) has no effect on STS activity in Caco2 or HCT116 lysates. Data represents mean ± SD. *n* = 3 independent experiments.](fphar-08-00103-g005){#F5}

As OATP2B1 and OATP4A1 were expressed at the highest concentrations compared to the other OATPs, we next performed siRNA knockdown of these two transporters in HCT116 cells to determine their importance on E~1~S uptake. We used HCT116 cells as they had high OATP2B1 and OATP4A1 expression without high expression of any other OATPs. Furthermore, HCT116 cells are readily transfected by lipofectamine for siRNA delivery. For both OATPs siRNA gave \< 95% knockdown as measured by qRT-PCR (**Figure [6A](#F6){ref-type="fig"}**). OATP2B1 knockdown did not significantly affect E~1~S uptake (**Figure [6B](#F6){ref-type="fig"}**), however OATP4A1 knockdown significantly reduced E~1~S uptake from 21.02 ± 3.12 to 8.93 ± 2.07 pmol/mg/h (*p* \< 0.01), suggesting this transporter may play a key role in E~1~S transport in CRC.

![**OATP4A1 knockdown in HCT116 cells blocks E~1~S transport. (A)** siRNA knockdown of OATP2B1 and OATP4A1 reduced transporter expression by over 95%. **(B)** In HCT116 cells OATP2B1 knockdown has no effect on E~1~S transport, however OATP4A1 knockdown inhibited E~1~S transport by 52.4%. Data represents mean ± SD. *n* = 3 independent experiments. ^∗∗^*p* \< 0.01 compared to control.](fphar-08-00103-g006){#F6}

STS Activity is Regulated by E~2~ Availability and GPER Action in CRC
---------------------------------------------------------------------

As steroid metabolism and estrogen action in the colon is poorly defined we next speculated whether estrogens may influence steroid sulfatase activity, as it has been reported to do in other malignancies ([@B38]). Thus we next examined how E~2~ starvation and subsequent E~2~ supplementation effects STS activity. HT29 cell treated with sFBS medium (i.e., estrogen starvation) demonstrated a trend toward reduction in STS activity, with this effect reversed when supplemented with E~2~ (**Figure [7A](#F7){ref-type="fig"}**). In HCT116 cells, 24 h of E~2~ (100 nM) treatment significantly (*p* \< 0.01) induced STS activity compared to sFBS controls (**Figure [7B](#F7){ref-type="fig"}**).

![**Steroid sulfatase activity is regulated by estrogen availability in CRC cell lines. (A)** E~2~ (100 nM) does not increase STS activity in HT29. **(B)** E~2~ (100 nM) significantly increase STS activity in HCT116 cells. **(C)** 24 h treatment of Tamoxifen (10 nM) and fulvestrant (1 mM) increases STS activity in HCT116 cells. **(D)** Colo205 and Caco2 cells express ERα, but not ERβ. HCT116 and HT29 cells do not express ERα or ERβ. The +ive control is MCF-7 protein. **(E)** GPER is expressed in HCT116 and HT29 cells. Data represents mean ± SD. *n* = 3 independent experiments. ^∗^*p* \< 0.05, ^∗∗^*p* \< 0.01 compared to sFBS control.](fphar-08-00103-g007){#F7}

We next attempted to inhibit this E~2~-induced increase in STS activity by treating HCT116 with Tamoxifen or fulvestrant co-administered with E~2~. Surprisingly, both Tamoxifen and fulvestrant significantly increased STS activity in HCT116 cells (**Figure [7C](#F7){ref-type="fig"}**) and neither compound had any effect on E~2~-induced STS activity. Tamoxifen (at 10 nM) increased STS activity to 6.43 ± 0.95 pmol/mg/h and fulvestrant (1 μM) increase activity to 7.84 ± 1.36 pmol/mg/h compared to 2.43 ± 0.31 pmol/mg/h.

Examination of the CRC cell lines ER status demonstrated that ERα protein expression was present in Caco2 cells, and lowly expressed in Colo205 cells. HCT116 and HT29 cells did not express ERα (**Figure [7D](#F7){ref-type="fig"}**). None of the cell lines expressed ERβ (**Figure [7D](#F7){ref-type="fig"}**). We also assessed the GPER status in our CRC cell lines. HCT116 and HT29 cells expressed GPER (**Figure [7E](#F7){ref-type="fig"}**), as did Caco2 and Colo205 (data not shown). Unedited immunoblots are shown in Supplementary Figure [1](#SM1){ref-type="supplementary-material"}. As both Tamoxifen and fulvastrant have been shown to be GPER agonist ([@B25]) we next examined whether the increased STS activity induced by these compounds could be inhibited by G15, a specific GPER antagonist ([@B5]). In HCT116 cells, G15 (1 μM) significantly inhibited the increase of STS activity induced by 24 h treatment with E~2~ (100 nM), the GPER agonist G1 (100 nM), Tamoxifen (10 nM), and fulvestrant (1 μM) (**Figure [8](#F8){ref-type="fig"}**). This suggests a potential novel positive estrogen metabolism feedback loop through GPER stimulation is present in CRC.

![**Stimulation of GPER increases STS activity in HCT116 cells.** E~2~ (100 nM), G1 (100 nM), Tamoxifen (10 nM), and fulvestrant (1 mM) induce increased STS activity in HCT116 cells. These effects are inhibited by the addition of the GPER antagonist G15 (1 mM). Data represents mean ± SD. *n* = 3 independent experiments. ^∗^*p* \< 0.05, ^∗∗^*p* \< 0.01.](fphar-08-00103-g008){#F8}

Discussion
==========

Hormone replacement therapy, usually a combination of equine E~1~S and progestins, may play a dual role in the incidence and progression of CRC. Initially protective against the development of CRC ([@B4]), once the malignancy is formed CRC may be estrogen responsive ([@B8]). Thus, defining how CRC transports and metabolizes estrogens, and the ER status of CRC, may define how this tissue responds to HRT. Here we demonstrate that CRC cell lines possess STS activity (see **Figure [2](#F2){ref-type="fig"}**) and are able to transport E~1~S (see **Figure [4](#F4){ref-type="fig"}**), most likely through OATP4A1 (see **Figure [6](#F6){ref-type="fig"}**), into cells. Furthermore, we show that STS activity is elevated by local E~2~ concentrations (see **Figure [7](#F7){ref-type="fig"}**) via GPER action. Finally we show that tamoxifen and fulvestrant, both GPER agonists, also elevate STS activity (see **Figure [8](#F8){ref-type="fig"}**) indicating that its use in breast cancer patients may have unwanted consequences in the colon.

Elevated STS expression has been demonstrated in breast ([@B22]), prostate ([@B21]) endometrial ([@B15]), and epithelial ovarian cancer ([@B29]). We demonstrate here for the first time that STS activity is present in both intact and lysed CRC cells, and this activity could be inhibited with STX64 (**Figure [2](#F2){ref-type="fig"}**). Although the role of STS activity and estrogens in CRC is not yet defined, our results, combined with evidence showing increased STS expression as a poor prognostic indicator in CRC patients ([@B32]), suggests STX64 as a potential therapeutic option for this disease. Indeed, STX64 has shown significant promise in hormone-dependent breast cancer patients ([@B35], [@B34]) with limited adverse events ([@B35]). Further Phase II trials of STX64 are currently ongoing in patients with hormone-dependent breast cancer.

Cell protein (from cell lysates) exhibited significantly greater STS activity compared to intact cells suggesting E~1~S cell membrane transport as the limiting factor in estrogen hydrolysis. Thus, OATP expression patterns in CRC may be a key regulator of E~1~S transport and subsequent estrogen action. Our results demonstrate OATP4A1, followed by OATP2B1, as the most abundantly expressed E~1~S transporters in CRC cell lines (**Figure [3](#F3){ref-type="fig"}**). OATP4A1 is up-regulated and hypomethylated in CRC compared to normal colon tissue ([@B28]), suggesting its importance in disease progression, and implying that E~1~S uptake through this transporter may influence tumor proliferation. Furthermore, OATP3A1 is down-regulated in CRC ([@B28]), and reflected in our results as low expression of this transporter is evident in all four cell lines. OATP1B3 correlates to the Gleason score as a marker of CRC dedifferentiation: higher OATP1B3 expression in the colon is associated with earlier tumor stage and improved tumor differentiation ([@B24]). We demonstrate low OATP1B3 expression in our cell lines, supporting a role for this transporter in early tumor stage as all four cell lines examined were derived from latter-stage tumors.

Once transported, E~1~S requires hydrolysis to form E~1~, and subsequently E~2~ via 17β-hydroxysteroid dehydrogenase activity. However, controversy surrounds how estrogens act in CRC. Evidence suggests ERα is either lowly expressed ([@B3]) or not present ([@B37]), and ERβ is down-regulated during CRC development from colon adenomas ([@B14]). Thus, we determined ER status in four CRC cell lines, showing that Caco2 and Colo205 cells have some ERα immunoreactivity (**Figure [7](#F7){ref-type="fig"}**). None of the cell lines expressed ERβ. As they did not express either ERα or ERβ, we selected HCT116 and HT29 cells and determined that they expressed GPER. As ERα and ERβ are not present in CRC, this suggests that estrogens may primarily act through GPER in CRC. Indeed, estrogen binding to GPER increases colonic transit time ([@B16]) and is associated with pain severity in irritable bowel disease ([@B27]). However, this is the first report of GPER stimulation having a functional molecular consequence in STS activity.

Intriguingly, E~2~ and G1, a specific GPER agonist, increased STS activity in HCT116 cell lines (**Figure [7](#F7){ref-type="fig"}**), suggesting a potential novel positive estrogen feedback loop is present within CRC. In theory, greater STS activity should result in increased local E~1~ and E~2~ synthesis. Little is known about the regulation of STS activity. STS can undergo various post-translational modifications resulting in greater activity ([@B36]), and this effect may be NF-κB regulated ([@B13]). However, there are no other reports that estrogen availability impacts STS activity. In breast cancer, GPER stimulation by tamoxifen does elevate the expression of aromatase ([@B2]), the enzyme involved in estrogen synthesis from androgen pre-cursors. It is with some interest then to see that tamoxifen also increased STS activity in HCT116 cell lines. As a selective ER modulator, tamoxifen is a first line therapy against hormone-dependent breast cancer. However, it has recently been shown that tamoxifen may act as a GPER agonist in tamoxifen-resistant tumors ([@B19]). Thus, tamoxifen-induced increase of STS activity, and therefore increasing local estrogen availability, in CRC and potentially other malignancies may represent a novel GPER-stimulated pathway regulating STS action. It will be of importance to further examine whether tamoxifen and fulvestrant induce STS activity via GPER stimulation, as this may represent a novel route for tamoxifen and fulvestrant resistance.

Conclusion
==========

We have demonstrated here that CRC cell lines can transport E~1~S and have sufficient STS activity to liberate E~1~. STS activity is possibly regulated by local estrogen availability through GPER stimulation, and this represents a novel positive estrogen feedback loop within CRC. These results have direct consequences for HRT therapy, suggesting that HRT may increase STS activity in the colon leading to potentially undesired effects through GPER action.
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